- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01388712
Lactobacillus Reuteri in Children With Constipation
The Assessment of Lactobacillus Reuteri Efficacy, Provided With Forlax, as Treatment of Incurable Constipation in Children 3-7 Years. Double Blind, Placebo-controlled, Randomized and Multicenter Trial
The most common cause of children chronic constipation is functional disorders. Functional constipation is diagnosed after excluding organic causes of constipation (anatomical, neurological, endocrinological) and identification of two symptoms defined by the Rome III criteria. There could be low number of bowel movements (below three times a week), defecation pain, fecal incontinence (once a week), stool consistency or occurrence of large diameter stools. The treatment is change of diet, defecation training and application of laxatives.
The probiotics are defined as living microorganisms, which provided in a proper doses should result in beneficial effect on a host health. The assessment of its characteristic is related to strain of bacteria affiliation.
Taking into the consideration that patients with constipation may experience microflora intestine disorders, using the probiotics can have the positive impact on process of treating this disease. The additional reason for using the probiotics during the constipation treatment is an influence of probiotics on movement of the alimentary canal.
In spite of proved effectiveness of some probiotics' strains further research are required, because clinical significance is ambiguous and the effect is confirmed among patients with short medical history. That's way the further analysis of probiotic Lactobacillus reuteri DSM 17938, which was successful treatment method of chronic constipation amongst children (infants) should be performed.
The primary aim of the study is the assessment of Lactobacillus reuteri DSM 17938 efficacy, provided with macrogol (Forlax), as treatment of constipation in 3-7 years old children. The baseline of estimation is the frequency comparison of bowel movement in children belonging into two groups: Lactobacillus reuteri treatment and placebo.
The secondary aim of the study is the assessment of frequency the additional symptoms connected with defecation disorders: such as: number of pain episodes during defecation, the intensity of pain, number of hard stools, number of fecal incontinence per week, number of macrogol (Forlax) pockets used.
The investigators believe that constipation treatment (laxatives- macrogol) with Lactobacillus reuteri has better efficacy that the same treatment without Lactobacillus reuteri in 3-7 years old children with medical history of chronic constipation.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Warsaw, Poland, 04-730
- Recruiting
- ChildrensMHIPoland
-
Contact:
- Jaroslaw Kierkus, Ph.D.
- Phone Number: +48 228157384
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Children 3-7 years old
- Occurrence less than three bowel movement per week
- Medical history from at least two months]
- Ineffective laxative treatment at least two months
- The parents approval for child participation in the study and for the treatment
Exclusion Criteria:
- Well-known, organic cause of constipation (i.e. hypothyroidism, Hirschprung disease, cystis fibrosis)
- Anatomic defects of the alimentary canal
- The surgery of the alimentary canal in the past
- Treatment of antibiotics/probiotics during last two weeks before start of the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
|
Patients, who met inclusion criteria, will receive an identical to probiotic looking and tasting placebo.
|
|
Active Comparator: Probiotics
Lactobacillus reuteri DSM 17938
|
Patients, who met inclusion criteria, will receive following medicaments during 8 weeks: Lactobacillus reuteri DSM 17938 in form of chewing (one tablets containing 10^8CFU).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of bowel movement per week, without fecal incontinence
Time Frame: 12 weeks
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The number of bowel movements per week
Time Frame: 12 weeks
|
Other secondary items are: the number of pain episodes during defecation per week, the number of hard stools, the number of fecal incontinence per week, the number of patients who have to change amount of drug or use of enema.
|
12 weeks
|
|
The number of pain episodes during defecation per week,
Time Frame: 12 weeks
|
12 weeks
|
|
|
The number of hard stools
Time Frame: 12 weeks
|
12 weeks
|
|
|
The number of fecal incontinence per week
Time Frame: 12 weeks
|
12 weeks
|
|
|
The number of patients who have to change amount of drug
Time Frame: 12 weeks
|
12 weeks
|
|
|
The number of patients who have to change use of enema.
Time Frame: 12 weeks
|
12 weeks
|
Collaborators and Investigators
Investigators
- Study Chair: Jaroslaw Kierkus, Ph.D., Children's Memorial Health Institute, Poland
- Principal Investigator: Agnieszka Wegner, M.D., Children's Memorial Health Institute, Poland
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CZDGA23.01.2011
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Functional Constipation
-
Institute of Medical Sciences and SUM HospitalNot yet recruitingFunctional Constipation | Constipation - Functional | Constipation Chronic Idiopathic | Fecal Impaction | Pediatric Functional ConstipationIndia
-
Wecare Probiotics Co., Ltd.Not yet recruiting
-
Federal University of Minas GeraisMax NutriRecruiting
-
Liaquat University of Medical & Health SciencesUniversità degli Studi dell'InsubriaNot yet recruiting
-
Universidad de AntioquiaNot yet recruitingConstipation - Functional
-
Eskisehir Osmangazi UniversitySehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research HospitalCompletedConstipation - FunctionalTurkey (Türkiye)
-
Ahi Evran University Education and Research HospitalActive, not recruitingConstipation - FunctionalTurkey (Türkiye)
-
Peking Union Medical College HospitalInstitute of Process Engineering, Chinese Academy of SciencesNot yet recruitingChronic Constipation | Constipation - Functional | Fecal Microbiota TransplantationChina
-
Peking Union Medical College HospitalRecruitingChronic Constipation | Constipation - Functional | Fecal Microbiota Transplantation (FMT)China
-
Zeynep Idil SevimliNot yet recruitingFunctional Constipation (FC)Turkey (Türkiye)
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AkesoNot yet recruitingAtopic DermatitisChina
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
Chong Kun Dang PharmaceuticalUnknownHypertension | DyslipidemiasKorea, Republic of
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States